121.40Open121.40Pre Close0 Volume11 Open Interest170.00Strike Price0.00Turnover72.62%IV24.38%PremiumJan 17, 2025Expiry Date64.28Intrinsic Value100Multiplier12DDays to Expiry57.12Extrinsic Value100Contract SizeAmericanOptions Type0.9934Delta0.0006Gamma3.63Leverage Ratio-0.0413Theta0.0569Rho3.60Eff Leverage0.0080Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet